<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Intensive chemotherapy has improved the prognosis of patients with <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e> </plain></SENT>
<SENT sid="1" pm="."><plain>The success rate of relapse treatment correlates with the length of first remission </plain></SENT>
<SENT sid="2" pm="."><plain>Thus early relapses and primarily refractory diseases have a grave prognosis </plain></SENT>
<SENT sid="3" pm="."><plain>New chemotherapeutic regimens could be useful for those patients </plain></SENT>
<SENT sid="4" pm="."><plain>Patients treated for newly diagnosed or relapsed <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e> with polychemotherapy regimen of the <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e>-BFM-studies containing induction, consolidation and high-dose <z:chebi fb="0" ids="28680">cytarabine</z:chebi> combined with <z:chebi fb="0" ids="50729">mitoxantrone</z:chebi> (HAM) and relapsed within 2 up to 31 months after the first CR entered a pilot trial, the so called IDA-FLAG regimen </plain></SENT>
<SENT sid="5" pm="."><plain>This regimen includes G-CSF (day 0 up to ANC &gt; 1000/microliter, 400 micrograms/m2.d), fludarabine (day 1-4, 30 mg/m2.d), high-dose <z:chebi fb="0" ids="28680">cytarabine</z:chebi> (day 1-4, 2000 mg/m2.d) and <z:chebi fb="0" ids="42068">idarubicin</z:chebi> (day 2-4, 12 mg/m2.d) </plain></SENT>
<SENT sid="6" pm="."><plain>10 patients aged 1,8 to 28,1 years (mean = 9,6 years) having the first (n = 8) or second relapse (n = 1) of <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e> or an <z:hpo ids='HP_0011009'>acute</z:hpo> <z:e sem="disease" ids="C0005699" disease_type="Neoplastic Process" abbrv="">blastcrisis</z:e> of <z:hpo ids='HP_0002863'>myelodysplastic syndrome</z:hpo> (n = 1) (FAB classification: M1/M2 = 3, M4/M5 = 5, M7 = 1, <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CMML</z:e> = 1) received 14 courses </plain></SENT>
<SENT sid="7" pm="."><plain>Overall, 7 patients achieved CR with a mean duration of 8,9 months (1-22 months), one patient showed a partial remission and two were nonresponders </plain></SENT>
<SENT sid="8" pm="."><plain>4 patients are in continuous CR for 7,5 to 22 months (mean = 13,2 months) </plain></SENT>
<SENT sid="9" pm="."><plain>3 patients got a bone marrow transplantation (allogenic = 2, autologous = 1) in CR following this treatment </plain></SENT>
<SENT sid="10" pm="."><plain>Toxicity was considerable, mainly bone marrow <z:mpath ids='MPATH_58'>aplasia</z:mpath> with <z:e sem="disease" ids="C0023530" disease_type="Disease or Syndrome" abbrv="">leucopenia</z:e> &lt; 1000/microliter for 15 to 40 days (mean = 26,1 days), <z:hpo ids='HP_0001875'>neutropenia</z:hpo> &lt; 500/microliter for 14 to 39 days (mean = 26,0 days) and <z:hpo ids='HP_0001873'>thrombocytopenia</z:hpo> &lt; 30,000/microliter for 14 to 90 days (mean = 36,5 days) </plain></SENT>
<SENT sid="11" pm="."><plain>Further important side effects were <z:hpo ids='HP_0001945'>fever</z:hpo>, mucositis and <z:hpo ids='HP_0002090'>pneumonia</z:hpo> </plain></SENT>
<SENT sid="12" pm="."><plain>One patient died from an fulminant aspergillus <z:hpo ids='HP_0100806'>sepsis</z:hpo> during long-term <z:hpo ids='HP_0001875'>neutropenia</z:hpo> </plain></SENT>
<SENT sid="13" pm="."><plain>The sequential administration of G-CSF, fludarabine, <z:chebi fb="0" ids="28680">cytarabine</z:chebi> and <z:chebi fb="0" ids="42068">idarubicin</z:chebi> is effective in treatment of relapsed <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e> in childhood and an advisable option prior to allogenic or autologous bone marrow transplantation </plain></SENT>
<SENT sid="14" pm="."><plain>With regard to the unfavorable prognosis of relapsed or refractory <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e> the toxicity of this regimen seems acceptable </plain></SENT>
</text></document>